Retatrutide reduces HbA1c, weight more than Ozempic in diabetes
Once-weekly retatrutide induced greater declines in HbA1c and body weight than Ozempic 2 mg for adults with type 2 diabetes, according to topline results from the phase 3 open-label TRASCEND-T2D-2 trial.
As Healio previously reported, the TRANSCEND-T2D-1 trial found that retatrutide (Eli Lilly), a subcutaneous GLP-1, GIP and glucagon triple receptor agonist, reduced HbA1c and body weight more than placebo for adults with type 2 diabetes. In TRANSCEND-T2D-2, 1,298 adults with type 2 diabetes who were unable to achieve glycemic control with metformin with or without an SGLT2 inhibitor were